Since its founding in 2009, REGENXBIO has been a leader in the gene therapy field, driven by our ongoing commitment to developing gene therapies that improve treatment options for people with significant unmet needs.
REGENXBIO’s gene therapy product candidates all utilize adeno-associated virus (AAV) viral vectors from our proprietary gene delivery platform, which we call our NAV Technology Platform. In addition to our internal product candidate programs, we also selectively license our NAV Vectors to other leading biotechnology companies.